H. B. Fuller (NYSE:FUL) Stock Rating Lowered by Wall Street Zen

H. B. Fuller (NYSE:FUL) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Monday.

Several other equities research analysts have also recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of H. B. Fuller in a research note on Monday, November 17th. UBS Group assumed coverage on shares of H. B. Fuller in a research note on Friday. They issued a “neutral” rating and a $60.00 price objective on the stock. Seaport Res Ptn upgraded shares of H. B. Fuller from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 26th. Finally, Citigroup upgraded shares of H. B. Fuller from a “neutral” rating to a “buy” rating and raised their target price for the stock from $62.00 to $70.00 in a research note on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, H. B. Fuller currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.20.

H. B. Fuller Price Performance

Shares of NYSE:FUL opened at $57.31 on Monday. H. B. Fuller has a one year low of $47.56 and a one year high of $78.68. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of 30.98, a PEG ratio of 1.05 and a beta of 1.13. The company has a 50-day simple moving average of $58.70 and a 200-day simple moving average of $58.56. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.18 and a current ratio of 1.93.

H. B. Fuller (NYSE:FUL) last issued its quarterly earnings results on Wednesday, April 13th. The specialty chemicals company reported $0.66 earnings per share (EPS) for the quarter. The firm had revenue of $725.90 million for the quarter. H. B. Fuller had a return on equity of 11.49% and a net margin of 3.28%. H. B. Fuller has set its FY 2022 guidance at $4.100-$4.350 EPS. On average, analysts predict that H. B. Fuller will post 4.07 EPS for the current year.

Insider Transactions at H. B. Fuller

In related news, VP Nathan D. Weaver sold 7,075 shares of the firm’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $58.38, for a total value of $413,038.50. Following the completion of the sale, the vice president owned 9,441 shares in the company, valued at $551,165.58. This trade represents a 42.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO John J. Corkrean sold 14,222 shares of the business’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $60.31, for a total transaction of $857,728.82. Following the sale, the chief financial officer directly owned 54,646 shares in the company, valued at approximately $3,295,700.26. This represents a 20.65% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 1.99% of the company’s stock.

Institutional Investors Weigh In On H. B. Fuller

A number of institutional investors and hedge funds have recently modified their holdings of the company. Cooke & Bieler LP raised its holdings in H. B. Fuller by 94.9% during the third quarter. Cooke & Bieler LP now owns 1,481,030 shares of the specialty chemicals company’s stock worth $87,795,000 after purchasing an additional 721,100 shares during the last quarter. Norges Bank acquired a new stake in H. B. Fuller in the second quarter valued at $40,584,000. UBS Group AG increased its position in shares of H. B. Fuller by 200.8% in the third quarter. UBS Group AG now owns 820,871 shares of the specialty chemicals company’s stock valued at $48,661,000 after buying an additional 548,017 shares in the last quarter. Cramer Rosenthal Mcglynn LLC raised its stake in shares of H. B. Fuller by 287.2% during the 3rd quarter. Cramer Rosenthal Mcglynn LLC now owns 371,650 shares of the specialty chemicals company’s stock worth $22,031,000 after buying an additional 275,654 shares during the last quarter. Finally, Kennedy Capital Management LLC raised its stake in shares of H. B. Fuller by 131.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 439,444 shares of the specialty chemicals company’s stock worth $26,050,000 after buying an additional 249,350 shares during the last quarter. Institutional investors and hedge funds own 95.93% of the company’s stock.

About H. B. Fuller

H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and other specialty chemical products. It operates through three segments: Hygiene, Health and Consumable Adhesives; Engineering Adhesives; and Construction Adhesives.